Details

Autor(en) / Beteiligte

• Shimizu, Yasuhiro
• Suzuki, Toshihiro
• Yoshikawa, Toshiaki
• Tsuchiya, Nobuhiro
• Sawada, Yu
• Endo, Itaru
• Nakatsura, Tetsuya

Titel

Cancer immunotherapy‐targeted glypican‐3 or neoantigens

Ist Teil von

• Cancer science, 2018-03, Vol.109 (3), p.531-541

Ort / Verlag

England: John Wiley & Sons, Inc

Erscheinungsjahr

2018

Link zum Volltext

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Immune checkpoint inhibitors have ushered in a new era in cancer therapy, although other therapies or combinations thereof are still needed for many patients for whom these drugs are ineffective. In this light, we have identified glypican‐3 an HLA‐24, HLA‐A2 restriction peptide with extreme cancer specificity. In this paper, we summarize results from a number of related clinical trials showing that glypican‐3 peptide vaccines induce specific CTLs in most patients (UMIN Clinical Trials Registry: UMIN000001395, UMIN000005093, UMIN000002614, UMN000003696, and UMIN000006357). We also describe the current state of personalized cancer immunotherapy based on neoantigens, and assess, based on our own research and experience, the potential of such therapy to elicit cancer regression. Finally, we discuss the future direction of cancer immunotherapy. In this manuscript, we provide a summary of the multiple, related clinical trials we have completed in Japan to test GPC3‐based immunotherapy against hepatocellular carcinoma, ovarian clear‐cell adenocarcinoma, and some pediatric cancers. We also describe the state‐of‐the‐art of personalized cancer immunotherapy, and discuss future directions.